We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
PIQRAY (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
PIQRAY
Date registered
Evaluation commenced
Decision date
Approval time
195 working days (255)
Active ingredients
alpelisib
Registration type
NCE/NBE
Indication
PIQRAY (film coated tablet) in combination with fulvestrant, is indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer with a PIK3CA mutation as detected by a validated test following progression on or after an endocrine-based regimen.